Retatrutide Triple Agonism: What the Phase 2 Trial Found—and Did Not Prove
A close reading of retatrutide’s GIP, GLP-1 and glucagon receptor pharmacology and the 48-week phase 2 obesity trial, including limitations and current…
Read source review →
Research Topic
Metabolic & Body Composition
Topic knowledge
Source-reviewed reading for metabolic & body composition
Continue from catalog navigation into editorial analysis, evidence records and quality-documentation guidance.
Showing 73–77 of 77 reviewed articles · Page 13 of 13
Tirzepatide in 2026: Approved Drug Evidence vs Research-Use Material
Why an FDA-approved tirzepatide medicine, a compounded product and a research-use catalog material are not interchangeable evidence categories.
Read source review →Tirzepatide Dual GIP/GLP-1 Signaling: Mechanism and Trial Endpoints Explained
An evidence-led explanation of tirzepatide dual receptor agonism and the endpoints measured in SURPASS and SURMOUNT trials, with clear limits on applying…
Read source review →How to Verify 5-Amino-1MQ Research Material: Identity, Purity and Lot Documentation
A practical laboratory guide to checking 5-Amino-1MQ identity, purity language, analytical methods and lot-specific documentation without confusing a catalog listing with a…
Read source review →5-Amino-1MQ and NNMT Inhibition: What the Preclinical Evidence Actually Shows
A source-led review of 5-Amino-1MQ as an NNMT inhibitor, separating enzyme, cell and mouse findings from claims that have not been demonstrated…
Read source review →Need a peptide for metabolic & body composition research?
If a target is not listed, submit the sequence, scale and specification for a custom-project feasibility review.